Ozempic not linked to increase in suicidal thoughts: US study
A recent U.S. federal study funded by the National Institutes of Health (NIH) and conducted by Case Western Reserve University reveals that individuals taking the diabetes and obesity drugs Ozempic and Wegovy, containing the active ingredient semaglutide, had a lower risk of suicidal thoughts compared to those on other medications for the same conditions. The analysis involved electronic medical records of over 1.8 million patients prescribed semaglutide or alternative drugs for obesity or diabetes between 2017 and 2022. Individuals on semaglutide exhibited a 49% to 73% lower risk of first-time or recurring suicidal thoughts during a six-month follow-up period. The study's focus was on patients taking semaglutide or other drugs for diabetes or obesity.
Reference: Wang, W., Volkow, N.D., Berger, N.A. et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med (2024). https://doi.org/10.1038/s41591-023-02672-2
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.